Effect Of Butylphthalide On Interleukin-6in Acute Ischemic Stroke Patients

Background and Purpose:The thrombolytic therapy in acute ischemic stroke is widly acknowleged. A high percentage of patients miss the opportunity to undergo thrombolysis when arrived in hospital. Therefore, it is necessary to explore the pathological links with other intervention therapy in acute cerebral infarction. Available studies showed that Butylphthalide involves in multiple links of pathology in cerebral ischemia by means of increasing regional cerebral blood flow, improving microcirculation of ischemia and cerebral energy metabolism of global cerebral ischemia, protecting mitochondrial function and inhibiting calcium influx. It has a certain protective effect on the acute cerebral infarction. We studied the effect of Butylphthalide on levels of Interleukin-6(IL-6) and hypersensitive C-reactive protein (hs-CRP) and platelet aggregation rate in acute ischemic stroke patients to explore the correlation of nerve function defect and IL-6.Metholds:A total of80cases of consecutive patients with cerebral infarction of internal carotid artery system within48hours were recruited, and randomly divided into treatment group and control group, while other20healthy people by physical examination were recruited as normal control group. The ischemic stroke group received conventional treatment such as antiplatelet aggregation, statin drugs, etc. The treatment group took Butylphthalide (200mg, three times a day) besides conventional treatment. We assessed the NIHSS scores30days before and after treatment and the mRS scores3mouths after treatment to observe the nervous function recovery. We also measured the levels of IL-6and hs-CRP and platelet aggregation rate one week before and after treatment, meanwhile we analysed the correlation between them and nerve function defect. Results:1. IL-6and hs-CRP levels and platelet aggregation rate in ischemic stroke group before treatment were higher than normal control group with significant difference(P<0.05). They decreased in both of ischemic stroke group after one week treatment, and the treatment group decreased more significantly than control group (P<0.05).2. There was no obvious difference in the degree of nerve function defect between the treatment group and control group at baseline. After treatment, the NIHSS and mRS scores in both group obviously decreased, while compared to control group, these scores decreased more significiantly in patients received the treatment of Butylphthalide (P<0.05).3. Positive correlation between ischemic stroke and the levels of IL-6and hs-CRP and platelet aggregation rate were observed (P<0.05).Conclusion:Butylphthalide significantly alimorated nerve function defect symptoms and decreased the levels of IL-6and hs-CRP and platelet aggregation rate in ischemic stroke patients. Particularly, there is positive correlation between the improvement of nerve function defect and the levels of IL-6and hs-CRP and platelet aggregation rate. Our results showed that Butylphthalide can promote the recovery of neural function by decreasing IL-6level, alleviating inflammation and inhibiting platelet aggregation in patient of acute ischemic stroke.